Sugi Predict

Sugi Predict / Compounds / SCHEMBL271673

SCHEMBL271673

SCHEMBL271673

O=S(=O)(Cl)Cc1c(Cl)cccc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1B1 P15121 3/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ TAAR1 Q96RJ0 2/20 0.43
▸ KMT2A Q03164 4/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ RECQL P46063 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.38
▸ ADRA2A P08913 2/20 0.37
▸ POLB P06746 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ HTR1A P08908 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ ADRA2B P18089 1/20 0.37
▸ ADRA2C P18825 1/20 0.37
▸ MAOA P21397 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16914843 0.86 KDM4E (0.54) AKR1B1TAAR1KMT2AMEN1KDM4E
SCHEMBL31568330 0.86 KDM4E (0.54) AKR1B1TAAR1KMT2AMEN1KDM4E
SCHEMBL8698751 0.83 AKR1B1 (0.47) AKR1B1SMN1; SMN2TAAR1KMT2AMEN1
SCHEMBL271277 0.81 RORC (0.39) AKR1B1KMT2AMEN1KDM4E
SCHEMBL2906762 0.81 AKR1B1 (0.50) AKR1B1SMN1; SMN2TAAR1KMT2AMEN1
SCHEMBL1272047 0.79 AKR1B1 (0.45) AKR1B1SMN1; SMN2TAAR1KMT2AMEN1
SCHEMBL6380044 0.79 TAAR1 (0.46) AKR1B1SMN1; SMN2TAAR1KMT2AMEN1
SCHEMBL271469 0.79 AR (0.33) AKR1B1TDP1CYP3A4MAPK1
SCHEMBL1272049 0.79 RECQL (0.46) AKR1B1SMN1; SMN2TAAR1KMT2AMEN1
Hydrochloric Acid SCHEMBL28259955 0.79 AKR1B1 (0.48) AKR1B1SMN1; SMN2TAAR1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240417379-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2024-12-19 — — US disclosed
US-12116351-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2024-10-15 — — US disclosed
US-20220380322-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2022-12-01 — — US disclosed
US-11434207-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2022-09-06 — — US disclosed
CN-108863959-B P2X4 receptor antagonists 日本化学药品株式会社 2021-11-30 — — CN disclosed
US-20200223806-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2020-07-16 — — US disclosed
CN-111333588-A P2X4 receptor antagonists 日本化学药品株式会社 2020-06-26 — — CN disclosed
US-10633349-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2020-04-28 — — US disclosed
CN-104066724-B P2X4 receptor antagonists 日本化学药品株式会社 2020-04-17 — — CN disclosed
CN-110483423-A P2X4 receptor antagonist NIPPON CHEMIPHAR CO 2019-11-22 — — CN disclosed
US-20010018447-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION 2001-08-30 — — US disclosed
EP-1039903-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-10-04 — — EP disclosed
EP-1003509-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-05-31 — — EP disclosed
EP-1003497-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-05-31 — — EP disclosed
WO-2000006557-A1 NOVEL PROCESS FOR MAKING IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-02-10 — — WO disclosed
WO-1999036069-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-07-22 — — WO disclosed
WO-1999011264-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-03-11 — — WO disclosed
WO-1999011253-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-03-11 — — WO disclosed
WO-1994018165-A1 SULFONAMIDE COMPOUNDS AS OPIOID K-RECEPTOR AGONISTS PFIZER INC. (US) 1994-08-18 — — WO disclosed
US-4483856-A Insecticidal N-substituted-2-(nitromethylene)-tetrahydro-2H-1,3-thiazines SHELL OIL COMPANY (US) 1984-11-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220380322-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 AKR1B1 1481/4885SMN1; SMN2 3967/4885TAAR1 310/4885
US-20240417379-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 AKR1B1 1541/4885SMN1; SMN2 3549/4885TAAR1 326/4885
US-12116351-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 AKR1B1 1481/4885SMN1; SMN2 3967/4885TAAR1 310/4885
US-20200223806-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 AKR1B1 1481/4885SMN1; SMN2 3967/4885TAAR1 310/4885
US-11434207-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 AKR1B1 1481/4885SMN1; SMN2 3967/4885TAAR1 310/4885
US-10633349-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 AKR1B1 1481/4885SMN1; SMN2 3967/4885TAAR1 310/4885
US-20010018447-A1 IL-8 RECEPTOR ANTAGONISTS CXCL8, CCR8, IL5 AKR1B1 1306/4885SMN1; SMN2 4530/4885TAAR1 672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.